Highlights:

• Incannex subsidiary, Clarion Clinics, has received Human Research Ethics Committee (HREC) endorsement for administration of psychedelic-assisted therapies for TRD and PTSD.
• HREC approval is required for the administration of psychedelic drugs in Australia.
• Clarion Clinics is the only dedicated psychedelic-assisted therapy clinic in Australia, with intentions to open more clinics across the country and internationally as legislation permits.
• Clarion Clinics team includes pre-eminent psychedelic researchers, psychologists and psychiatrists whose expertise can not easily be replicated in Australia.
• Interest in treatments continues to rise considerably reflecting the high demand for this novel therapy.
• The Melbourne clinic fit-out is complete and the clinical and administrative teams in place.

MELBOURNE, Australia and NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (‘Incannex’ or ‘the Company’) a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic assisted psychotherapies for unmet needs is pleased to announce that it has received ethics board endorsement for psychedelic assisted therapy at its first clinic based in Melbourne, Australia, a city of approximately 5.2M people.

In order to prescribe schedule-8 drugs under the Therapeutic Goods Administration (TGA) Authorised Prescriber Scheme, psychiatrists are required to receive HREC endorsement for their qualifications, experience, the qualifications and experience of the treatment team, and the protocols to be used in the treatment of patients with psychedelic compounds. Clarion is pleased to announce that it has received HREC endorsement for both Psilocybin and MDMA assisted therapy for the treatment of Treatment Resistant Depression (TRD) and Post-Traumatic Stress Disorder respectively (PTSD).

The Australian TGA, which is akin to the FDA in the United States, selectively down-scheduled psilocybin for the treatment of TRD and MDMA for the treatment of PTSD from schedule 9 to schedule 8 in July 2023, which allows authorised psychiatrists to prescribe both drugs under the Authorised Prescriber Scheme.

The Melbourne Clarion Clinic will be the first dedicated Psychedelic-assisted therapy clinic in Australia. Located on the Yarra Riverfront in Abbottsford, Melbourne, it has been designed and fitted out specifically to facilitate an optimal environment for psychedelic-assisted therapy. With seven treatments rooms and a group therapy room, the clinic is a commercial scale prototype and has the capacity to treat approximately 600 people per annum in normal working hours and substantially more in extended hour operations. Future clinics are intended to be significantly larger.

Clarion has received a substantial number of expressions of interest in treatment submissions from potential patients since opening its application process earlier this year. It’s estimated that 670,000 people suffer from either TRD, PTSD or both in Australia at any given time and many patients do not respond to traditional treatments for both indications, or experience diminishing efficacy. Psychedelic-assisted therapy has been proved through clinical trials to help a substantial proportion of people who do not respond to traditional treatments.

“This treatment is potentially life-changing for hundreds of thousands of people in Australia and tens of millions globally. Clarion is at the leading edge of mental healthcare, has the right protocols and an experienced team ready to help people through these challenging conditions,” Peter Widdows, IHL Director responsible for Clarion Clinics, said.

“Being the first entrants into this field in Australia will position Incannex, via Clarion, at the forefront of psychedelic-assisted therapies and will facilitate the smooth expansion into more clinics nation-wide as we roll out the treatment protocols and business model. We believe regulations regarding the use of psychedelic-assisted therapies will change in other countries too, following Australia’s lead. Clarion will be well placed to take advantage of this,” Joel Latham, CEO and President of IXHL, said.

This announcement has been approved for release to NASDAQ by the Incannex Board of Directors.

About Incannex Healthcare Inc.

Incannex is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications.

U.S. FDA approval and registration, subject to ongoing clinical success, is being pursued for each drug and therapy under development. Each indication under investigation currently has no, or limited, existing registered pharmacotherapy (drug) treatments available to the public and represent major global economic opportunities to Incannex and its shareholders.

Incannex has a strong patent filing strategy in place as it develops its products and therapies in conjunction with its medical and scientific advisory board and partners. The Company holds 19 granted patents and 30 pending patent applications. Incannex is listed on the NASDAQ as IXHL

Website: www.incannex.com.au
Investors: This email address is being protected from spambots. You need JavaScript enabled to view it.

Forward-looking statements
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations and estimates, as well as the beliefs and assumptions of management. The forward-looking statements included in this press release represent Incannex's views as of the date of this press release. Incannex anticipates that subsequent events and developments may cause its views to change. Incannex undertakes no intention or obligation to update or revise any forward-looking statements, whether as of a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Incannex's views as of any date after the date of this press release.

Contact Information:

Investor Relations Contact – United States
Alyssa Factor
Edison Group
+1 (860) 573 9637